pharm edaily

[Kim Jiwan, Edaily Reporter] JETEMA’s earnings momentum is expected to take off in earnest this year.



According to the Financial Supervisory Service’s electronic disclosure on the 4th, JETEMA recorded consolidated revenue of KRW 68.5 billion and an operating profit of KRW 4.4 billion last year. These figures represent increases of 16.6% and 68.3%, respectively, compared to the previous year.

On a standalone basis, the company posted revenue of KRW 64.0 billion and an operating profit of KRW 9.3 billion, marking year-over-year growth of 8.9% and 78.0%, respectively. The increase in earnings was mainly driven by a significant surge in overseas sales in the filler segment.

JETEMA expects its earnings momentum to strengthen from this year onward.

A JETEMA representative stated, “Since our listing in 2019, our revenue has maintained double-digit annual growth rates. However, operating profit fell short of expectations due to initial costs associated with securing marketing channels ahead of our entry into the domestic botulinum toxin market, as well as strategic working capital expenditures for our domestic and overseas subsidiaries to expand our market presence.”

He added, “We expect a breakthrough in our earnings performance this year, beginning with the domestic launch of our botulinum toxin product, JETEMA The Toxin. In particular, we are actively preparing for overseas market expansion.” He further noted, “Turkiye will be our first overseas entry market this year, following our five-year botulinum toxin sales agreement worth KRW 80 billion. We anticipate toxin sales to increase by 40~50% this year alone.”

JETEMA also expressed optimism regarding the growth prospects of its filler business.

The company representative stated, “Our flagship product, e.p.t.q. (Epitique), will experience rapid sales growth as we expand into the Chinese and Latin American markets. We plan to establish our market position in China, one of the world’s largest beauty markets, by securing regulatory approval within the first half of this year and generating immediate sales.”

On January 17, JETEMA signed a five-year, KRW 40 billion distribution and promotion agreement with Huadong Aesthetics, a leading Chinese beauty distribution company.

JETEMA aims to generate more than KRW 40 billion in e.p.t.q. sales in China. In the Latin American market, the company expects to complete the approval process for its new filler product within the first quarter of this year, anticipating additional annual sales of over KRW 5 billion.

Kim Jae-young, CEO of JETEMA, stated, “By entering new markets this year, we aim to achieve significant earnings improvement and global market expansion, ultimately reaching our first-ever KRW 100 billion in annual revenue.”